Retinopathy of Prematurity Clinical Trial
Official title:
The Effects of Mydriatic Eye Drops on Cerebral Blood Flow and Oxygenation in Retinopathy of Prematurity Examinations: A Prospective Observational Trial
Retinopathy of prematurity (ROP) is a retinal disorder of preterm neonates and a potential cause of blindness. As early diagnosis and treatment preserve vision, very low birth weight infants must be screened for ROP. Mydriatic eye drop administration is essential to perform funduscopic evaluations. The most commonly used mydriatic drops for pupil dilatation are 0.5-1.0% tropicamide and/or 0.5-1.0% phenylephrine or 0.2-1.0% cyclopentolate. Phenylephrine, an alpha-1 sympathomimetic agonist, is readily absorbed from conjunctival mucosa and has a potent systemic vasopressor effect. Tropicamide causes cycloplegia by inhibition of ciliary muscle contraction and has a short acting para-sympatholytic effect. Systemic absorption of mydriatic eye drops has been associated with cardiovascular, respiratory and gastrointestinal adverse effects. Systemic side effects include apnea, desaturation, increased heart rate and blood pressure, delayed gastric emptying, and feeding intolerance. The data about the effects of mydriatics on cerebral blood flow and tissue oxygenation are sparse. Cerebral blood flow autoregulation depends in part on the adrenergic and cholinergic control of cerebral vasculature, but whether mydriatics have an effect on cerebral haemodynamics is unknown. Near-infrared spectroscopy and Doppler ultrasonography (US) are non-invasive methods commonly used for neuromonitorization in NICUs. The regional blood flow changes measured using Doppler US have been reported to be associated with cerebral oxygenation and indicate a high correlation with NIRS in newborns. The aim of this study was to evaluate the effects of mydriatic eye drops on cerebral oxygenation and blood flow in preterm infants by NIRS and Doppler US.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05043077 -
Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening
|
Phase 4 | |
| Completed |
NCT04838665 -
Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study
|
Phase 4 | |
| Completed |
NCT04408807 -
Stress Induced by Screening for Retinopathy of Prematurity - Should Speculum and Indentation Rather be Avoided
|
N/A | |
| Recruiting |
NCT03083431 -
Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity
|
Phase 2 | |
| Enrolling by invitation |
NCT04985448 -
Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data
|
||
| Recruiting |
NCT02090322 -
Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1
|
N/A | |
| Completed |
NCT00872664 -
Skin and Serum Carotenoids in Preterm Infants Fed on a Formula Supplemented With Carotenoids
|
N/A | |
| Unknown status |
NCT00254176 -
Cysteine Supplementation in Critically Ill Neonates
|
Phase 2/Phase 3 | |
| Completed |
NCT06452524 -
Prematurity and Ophthalmological Changes
|
||
| Completed |
NCT04101721 -
Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
|
Phase 3 | |
| Enrolling by invitation |
NCT02050971 -
Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates
|
Phase 1 | |
| Terminated |
NCT01335113 -
A Scan Ultrasonography in the Evaluation of Retinopathy of Prematurity
|
||
| Active, not recruiting |
NCT00027222 -
The Early Treatment for Retinopathy of Prematurity Study (ETROP)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06109285 -
Validation of i-ROP DL to Detect More Than Mild ROP
|
N/A | |
| Completed |
NCT02014454 -
Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature
|
Phase 2 | |
| Completed |
NCT01861470 -
REDEXAM - Reducing Painful Eye Examinations in Preterm Infants
|
N/A | |
| Terminated |
NCT00634972 -
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
|
Phase 4 | |
| Completed |
NCT05701124 -
Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity
|
Phase 3 | |
| Completed |
NCT04092127 -
Pain of Premature Babies and RetCam (DOLICAM)
|
||
| Completed |
NCT04621136 -
PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity
|
Phase 1/Phase 2 |